Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia

A Pediatric Oncology Group pilot feasibility study

Eric S. Sandler, Alan Homans, Lynda Mandell, Michael Amylon, Donna A. Wall, Meenakshi Devidas, George R. Buchanan, Jeffrey M. Lipton, Amy L. Billett

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis. The best therapy for these patients is not known. This study was designed to evaluate the feasibility of enrolling children with recurrent ALL in a standardized treatment protocol that included receipt of a hematopoietic stem cell transplant (HSCT). Procedure: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin. A common conditioning regimen was used for all patients. Results: Twenty-eight patients from eight institutions were enrolled. Fourteen patients did not receive a transplant during the study, because of toxicity (4), relapse (1), inadequate purging (1), and parental or physician preference for an alternative donor transplant (8). Six patients received allogeneic HSCTs. Five of them have remained in remission for a median of 78 months. Eight patients received autologous HSCTs purged with B4-blocked ricin. Four have remained in remission for a median of 94 months. Of the nine patients who received alternative donor transplants, only two remain in remission. Conclusion: We conclude that well designed and controlled prospective studies are necessary to define the role of HSCTs in children with recurrent ALL. In order to be successful, such studies must have the full support of participating centers. Autologous HSC transplantation may have a role in the treatment of relapsed ALL, but further studies are needed.

Original languageEnglish (US)
Pages (from-to)210-215
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume28
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Hematopoietic Stem Cell Transplantation
Feasibility Studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Pediatrics
Recurrence
Hematopoietic Stem Cells
Transplants
Ricin
Tissue Donors
Autologous Transplantation
Clinical Protocols
HLA Antigens
Siblings
Prospective Studies
Physicians
Therapeutics

Keywords

  • Acute lymphoblastic leukemia
  • Hematopoietic stem cell transplant
  • Immunotoxin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia : A Pediatric Oncology Group pilot feasibility study. / Sandler, Eric S.; Homans, Alan; Mandell, Lynda; Amylon, Michael; Wall, Donna A.; Devidas, Meenakshi; Buchanan, George R.; Lipton, Jeffrey M.; Billett, Amy L.

In: Journal of Pediatric Hematology/Oncology, Vol. 28, No. 4, 04.2006, p. 210-215.

Research output: Contribution to journalArticle

Sandler, Eric S. ; Homans, Alan ; Mandell, Lynda ; Amylon, Michael ; Wall, Donna A. ; Devidas, Meenakshi ; Buchanan, George R. ; Lipton, Jeffrey M. ; Billett, Amy L. / Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia : A Pediatric Oncology Group pilot feasibility study. In: Journal of Pediatric Hematology/Oncology. 2006 ; Vol. 28, No. 4. pp. 210-215.
@article{b34af36158f0452f93f6ffab076386c5,
title = "Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: A Pediatric Oncology Group pilot feasibility study",
abstract = "Background: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis. The best therapy for these patients is not known. This study was designed to evaluate the feasibility of enrolling children with recurrent ALL in a standardized treatment protocol that included receipt of a hematopoietic stem cell transplant (HSCT). Procedure: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin. A common conditioning regimen was used for all patients. Results: Twenty-eight patients from eight institutions were enrolled. Fourteen patients did not receive a transplant during the study, because of toxicity (4), relapse (1), inadequate purging (1), and parental or physician preference for an alternative donor transplant (8). Six patients received allogeneic HSCTs. Five of them have remained in remission for a median of 78 months. Eight patients received autologous HSCTs purged with B4-blocked ricin. Four have remained in remission for a median of 94 months. Of the nine patients who received alternative donor transplants, only two remain in remission. Conclusion: We conclude that well designed and controlled prospective studies are necessary to define the role of HSCTs in children with recurrent ALL. In order to be successful, such studies must have the full support of participating centers. Autologous HSC transplantation may have a role in the treatment of relapsed ALL, but further studies are needed.",
keywords = "Acute lymphoblastic leukemia, Hematopoietic stem cell transplant, Immunotoxin",
author = "Sandler, {Eric S.} and Alan Homans and Lynda Mandell and Michael Amylon and Wall, {Donna A.} and Meenakshi Devidas and Buchanan, {George R.} and Lipton, {Jeffrey M.} and Billett, {Amy L.}",
year = "2006",
month = "4",
doi = "10.1097/01.mph.0000212902.84146.81",
language = "English (US)",
volume = "28",
pages = "210--215",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia

T2 - A Pediatric Oncology Group pilot feasibility study

AU - Sandler, Eric S.

AU - Homans, Alan

AU - Mandell, Lynda

AU - Amylon, Michael

AU - Wall, Donna A.

AU - Devidas, Meenakshi

AU - Buchanan, George R.

AU - Lipton, Jeffrey M.

AU - Billett, Amy L.

PY - 2006/4

Y1 - 2006/4

N2 - Background: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis. The best therapy for these patients is not known. This study was designed to evaluate the feasibility of enrolling children with recurrent ALL in a standardized treatment protocol that included receipt of a hematopoietic stem cell transplant (HSCT). Procedure: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin. A common conditioning regimen was used for all patients. Results: Twenty-eight patients from eight institutions were enrolled. Fourteen patients did not receive a transplant during the study, because of toxicity (4), relapse (1), inadequate purging (1), and parental or physician preference for an alternative donor transplant (8). Six patients received allogeneic HSCTs. Five of them have remained in remission for a median of 78 months. Eight patients received autologous HSCTs purged with B4-blocked ricin. Four have remained in remission for a median of 94 months. Of the nine patients who received alternative donor transplants, only two remain in remission. Conclusion: We conclude that well designed and controlled prospective studies are necessary to define the role of HSCTs in children with recurrent ALL. In order to be successful, such studies must have the full support of participating centers. Autologous HSC transplantation may have a role in the treatment of relapsed ALL, but further studies are needed.

AB - Background: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis. The best therapy for these patients is not known. This study was designed to evaluate the feasibility of enrolling children with recurrent ALL in a standardized treatment protocol that included receipt of a hematopoietic stem cell transplant (HSCT). Procedure: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin. A common conditioning regimen was used for all patients. Results: Twenty-eight patients from eight institutions were enrolled. Fourteen patients did not receive a transplant during the study, because of toxicity (4), relapse (1), inadequate purging (1), and parental or physician preference for an alternative donor transplant (8). Six patients received allogeneic HSCTs. Five of them have remained in remission for a median of 78 months. Eight patients received autologous HSCTs purged with B4-blocked ricin. Four have remained in remission for a median of 94 months. Of the nine patients who received alternative donor transplants, only two remain in remission. Conclusion: We conclude that well designed and controlled prospective studies are necessary to define the role of HSCTs in children with recurrent ALL. In order to be successful, such studies must have the full support of participating centers. Autologous HSC transplantation may have a role in the treatment of relapsed ALL, but further studies are needed.

KW - Acute lymphoblastic leukemia

KW - Hematopoietic stem cell transplant

KW - Immunotoxin

UR - http://www.scopus.com/inward/record.url?scp=33646929826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646929826&partnerID=8YFLogxK

U2 - 10.1097/01.mph.0000212902.84146.81

DO - 10.1097/01.mph.0000212902.84146.81

M3 - Article

VL - 28

SP - 210

EP - 215

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -